Sign In
Buy MLTX
$19.02
-0.340 (-1.76%)
At Close: Jul 24, 2026
ZUG, Switzerland, February 2, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies
MoonLake Immunotherapeutics (NASDAQ:MLTX) versus Nuvation Bio (NYSE:NUVB) Critical Review
03:30am, Sunday, 18'th Jan 2026
Nuvation Bio (NYSE: NUVB - Get Free Report) and MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 9.6% – Should You Buy?
03:14am, Sunday, 11'th Jan 2026
Shares of MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) shot up 9.6% during trading on Friday. The stock traded as high as $16.29 and last traded at $15.7210. 1,836,121 shares traded ha
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
08:15am, Friday, 09'th Jan 2026
MoonLake regains momentum after the FDA Type B meeting allows BLA submission for sonelokimab in HS without additional trials. MLTX is de-risked, with a BLA submission targeted for 2H26, removing a maj
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
02:06pm, Thursday, 08'th Jan 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX) on Thursday received U.S. Food and Drug Administration (FDA) feedback regarding the clinical evidence strategy for Sonelokimab (SLK) in Hidradenitis Suppurat
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
08:00am, Thursday, 08'th Jan 2026
MoonLake requested a Type B meeting with the U. S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Appli
Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX)
03:49pm, Monday, 15'th Dec 2025
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Im
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
12:00pm, Monday, 15'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX.
LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors
10:20am, Monday, 15'th Dec 2025
LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MoonLake Immunotherapeutics, Inc., (“MoonLake” or the "Company") (NASDAQ: MLTX) investors of a class action on behalf of
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
09:34am, Monday, 15'th Dec 2025
NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the �
NEW YORK , Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX durin
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
08:55am, Monday, 15'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)---- $MLTX--MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm.
